LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Akcijų sąrašas・Cogent Biosciences Inc

Cogent Biosciences Inc

Atidarymo kaina

38.79 -1.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

38.16

Max

39.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.4M -81M
Pelnas, tenkantis vienai akcijai	-0.5
Pelno marža	-1,582.642
Darbuotojai	205
EBITDA	-6.8M -79M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+8.53% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.9B 6.1B
Ankstesnė atidarymo kaina	40.11
Ankstesnė uždarymo kaina	38.79

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

4.88 / 5.87 Palaikymas ir pasipriešinimas

Cogent Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-04 20:41; UTC

Uždarbis

Pagrindinės rinkos jėgos

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

2025-12-04 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

2025-12-04 17:43; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

2025-12-04 17:01; UTC

Uždarbis

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

2025-12-04 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

2025-12-04 23:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 21:48; UTC

Rinkos pokalbiai

Scales Hits Mark With Earnings Guidance -- Market Talk

2025-12-04 21:37; UTC

Uždarbis

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

2025-12-04 21:36; UTC

Uždarbis

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

2025-12-04 20:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 20:15; UTC

Rinkos pokalbiai

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

2025-12-04 20:04; UTC

Rinkos pokalbiai

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

2025-12-04 19:54; UTC

Rinkos pokalbiai

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

2025-12-04 19:33; UTC

Rinkos pokalbiai

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

2025-12-04 18:58; UTC

Rinkos pokalbiai

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

2025-12-04 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-04 16:41; UTC

Rinkos pokalbiai

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

2025-12-04 16:33; UTC

Rinkos pokalbiai

Uždarbis

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Akcijų palyginimas

Kainos pokytis

Cogent Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

8.53% į viršų

12 mėnesių prognozė

Vidutinis 42.5 USD 8.53%

Aukščiausias 65 USD

Žemiausias 20 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cogent Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Cogent Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

4.88 / 5.87Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.